Industry funding biases drug trial studies in favor of sponsors' products

February 21, 2017

The review, which adds 27 studies to update a previous Cochrane review, confirms earlier analyses by "providing definitive evidence that pharmaceutical industry funding of drug studies biases the results and conclusions to look favourable towards the drug of the sponsor," said senior author, Professor Lisa Bero of the University of Sydney's Charles Perkins Centre.

The authors note there are several potential ways that sponsors can influence the outcome of a study, including the framing of questions, the design of a study, the conduct of a study, how data are analysed, selective reporting of favourable results, and "spin" in reporting .

Also, while some journals now require that the role of the sponsor in the design, conduct and publication of the study be described, this practice is not widespread.

Professor Bero said the key concern associated with industry-sponsored research evaluating drugs and medical devices was that there were no standard tools or validated criteria that include industry sponsorship as a risk of bias for such studies.

"We need bias assessments tools for drug studies that take funding source into account," Professor Bero said. "Currently, we have no validated way to detect or evaluate these subtle but systematic biases."

Key findings

Compared to non-industry sponsored studies, industry sponsored and medical device studies:

  • More often had efficacy results that were more favourable to the sponsor's product (relative risk 1.27, confidence interval 1.19-1.37)
  • More often had favourable overall conclusions (relative risk 1.34, confidence interval 1.19-1.51)
  • Had less agreement between stated results and overall conclusions (relative risk 0.83, confidence interval 0.70-0.98).

Co-author to the review, Dr Joel Lexchin, Professor Emeritus of York University, said the findings were especially concerning for patients and doctors.

"Our views about the effectiveness and safety of many medicines may be distorted. Medicines may be both less safe and less effective than we think to the extent that the evidence about them comes from the companies making them," he said.

Explore further: Analysis of reports quantitatively comparing food-industry sponsored studies

Related Stories

Commercial interests may drown out patients' voices

January 17, 2017

Researchers from the University of Sydney and Bond University are urgently calling for greater independence and transparency around industry-sponsored patient advocacy groups, following a growing amount of evidence which ...

Recommended for you

Marathon running may cause short-term kidney injury

March 28, 2017

According to a new Yale-led study, the physical stress of running a marathon can cause short-term kidney injury. Although kidneys of the examined runners fully recovered within two days post-marathon, the study raises questions ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.